|
PF-56339 |
HOPRIX EN OCUVIAL 0.005% Solución oftálmica |
2026-12-16 |
|
Laboratorios Lansier, S. A. C |
Perú
|
Droguería Kamilsa |
Lansier Gt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-57262 |
XALOPTIC 0.005% Solución Oftálmica |
2024-09-30 |
|
Laboratorios Lansier, S. A. C |
Perú
|
Droguería Kamilsa |
Lansier Gt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56220 |
SYSTALAN ULTRA Solución oftálmica |
2024-01-04 |
|
Laboratorios Lansier, S. A. C |
Perú
|
Droguería Kamilsa |
Lansier Gt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59976 |
ASTEROSS EN OCUVIAL 0.5% Solución oftálmica |
2026-09-02 |
|
Vitaline S.A.C. |
Perú
|
Droguería Kamilsa |
Lansier Gt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-50317 |
METILPREDNISOLONA VITALIS 500 mg Polvo esteril para solución inyectable |
2024-07-14 |
|
Vitalis S.A. C.I. |
Colombia
|
Centrino Pharma |
Futura Farma |
Vitalis |
Polifarma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-50440 |
ACICLOVIR Vitalis 250 mg Polvo liofilizado para reconstituir a solución inyectable |
2024-07-29 |
|
Vitalis S.A. C.I. |
Colombia
|
Orion Medical |
MAVISA PHARMACEUTICALS |
A R Pharma |
Centrino Pharma |
Vitalis |
Polifarma |
Refasa |
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-51689 |
AMIKACINA VITALIS 500 mg /2 mL Solución inyectable |
2025-07-31 |
|
Vitalis S.A. C.I. |
Colombia
|
Orion Medical |
A R Pharma |
Centrino Pharma |
Futura Farma |
Vitalis |
Polifarma |
Refasa |
Repremedh Representaciones Médicas Hospitalarias |
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-53316 |
CEFEPIMA Vitalis 2 g Polvo para Solución inyectable |
2021-09-26 |
|
Vitalis S.A. C.I. |
Colombia
|
Centrino Pharma |
Futura Farma |
Vitalis |
Polifarma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-53454 |
NITROGLICERINA Vitalis 50 mg/10 mL Solución inyectable |
2021-11-02 |
|
Vitalis S.A. C.I. |
Colombia
|
Centrino Pharma |
Futura Farma |
Vitalis |
Polifarma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-53911 |
ROWECEF IM 1 g Polvo y Solución para Uso Parenteral |
2026-09-29 |
|
Laboratorios Rowe S.R.L. |
Colombia
|
Leterago |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|